FISCHER vs NOVARTIND: Stock Comparison

Fischer Medical Ventures Limited vs Novartis India Limited

Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings

Novartis India Limited is the larger company by market capitalisation. Fischer Medical Ventures Limited shows faster revenue growth, while Novartis India Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Fischer Medical Ventures Limited and Novartis India Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, FISCHER is more favourable on 3 of 13 scored metrics and NOVARTIND on 10These counts are context-free and are not an overall rating.

Key Differences

Market Cap
NOVARTIND is the larger company
₹4,062 Cr vs ₹2,486 Cr
P/E Ratio
NOVARTIND has a lower P/E
41.85x vs 80.98x
P/B Ratio
NOVARTIND has a lower P/B
5x vs 6.48x
EPS
NOVARTIND has higher earnings per share
₹37.76 vs ₹0.45
Dividend Yield
NOVARTIND has a higher dividend yield
1.7% vs 0.01%
Revenue Growth (TTM YoY)
FISCHER has faster revenue growth
98.7% vs 8%
EPS Growth (TTM YoY)
FISCHER has faster EPS growth
0% vs -13.8%
Qtr Sales Growth
FISCHER has stronger quarterly sales growth
98.8% vs 7.95%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricFISCHERNOVARTIND
SectorHealthcareHealthcare
IndustryMedical Equipment & SuppliesPharmaceuticals

Price

MetricFISCHERNOVARTIND
Live Price₹37.94₹1,641.2
Day Change-2.79%-1.9%
Volume21.83 L54,369
52-Week High₹1,194.4₹1,780
52-Week Low₹31.05₹950
Distance from 52W High-96.82%-7.8%

Valuation

MetricFISCHERNOVARTIND
Market Cap₹2,486 Cr₹4,062 Cr
P/E Ratio80.98x41.85x
P/B Ratio6.48x5x
EPS₹0.45₹37.76
Book Value₹5.96₹331.34
Dividend Yield0.01%1.7%

Growth

MetricFISCHERNOVARTIND
Revenue Growth (TTM YoY)98.7%8%
EPS Growth (TTM YoY)0%-13.8%
Qtr Sales Growth98.8%7.95%
Qtr Profit Growth-642%-13.8%

Profitability & Leverage

MetricFISCHERNOVARTIND
ROE8.59%11.6%
ROCE11.4%16.2%
Net Margin6.79%26.3%
Operating Margin14%26.6%
Debt to Equity0.28x0x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricFISCHERNOVARTIND
Promoter Holding11.46% 0.82 pp0%
FII Holding4.97% 0.12 pp0.17% 0.02 pp
DII Holding1.38% 0.02 pp0.53% 0.11 pp
Public Holding31.5% 0.49 pp28.61% 0.11 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Fischer Medical Ventures Limited and Novartis India Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.